Omeros (NASDAQ:OMER) leaped on Tuesday as the biopharmaceutical company reported positive mid-stage study results of its drug to treat disorders characterized by excessive blood clots.
Shares jumped 63% to $23.69 at 1:49 a.m. in New York.
The antibody therapy, OMS721, is designed to clear blood clots from bodily organs, treating a group of very rare ailments called thrombotic microangiopathies, or TMAs.
Omeros said in a statement on Tuesday that in its latest trial of OMS721, three patients were treated. Two patients have atypical hemolytic uremic syndrome, or aHUS, and one has thrombotic thrombocytopenic purpura, or TTP, and were treated for four weeks.
The study had no placebo, the Seattle, Washington-based company said in the statement. Omeros measured change from baseline in platelet count as a primary endpoint, similar to the method rival Alexion Pharmaceuticals Inc. used to obtain approval for its aHUS drug Soliris.
Omeros said that in the mid-stage trial, platelet counts in all three patients were normal after the treatment period, with a an increase from baseline of about 47% in mean platelet count for the two aHUS patents and 63% for the TTP patient.
Omeros said there have been no confirmed clinically meaningful drug-related adverse events in any OMS721 trials.
Compassionate use in aHUS patients has begun, the company said, and it
Omeros expects to discuss its late-stage trial with the Food & Drug Administration later this year.
Omeros has a total of 12 programs in its pipeline.